Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer

Bibliography

• Hassett MJ, O'Malley AJ, Pakes JR, Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-17
   PubMed Web of Science ®Google Scholar
• Farquhar CM, Marjoribanks J, Lethaby A, Basser R. High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. Cancer Treat Rev 2007;33:325-37
   PubMed Web of Science ®Google Scholar
• Bai Z, Gust R. Breast cancer, estrogen receptor and ligands. Arch Pharm (Weinheim) 2009;342:133-49
   PubMed Web of Science ®Google Scholar
• Trompier D, Chang XB, Barattin R, Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res 2004;64:4950-6
   PubMed Web of Science ®Google Scholar
• Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-24
   PubMed Web of Science ®Google Scholar
• Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005;5:30
   PubMed Web of Science ®Google Scholar
• Huang Y, Sadee W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett 2006;239:168-82
   PubMed Web of Science ®Google Scholar
• Sauna ZE, Smith MM, Muller M, The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001;33:481-91
   PubMed Web of Science ®Google Scholar
• Dexter DW, Reddy RK, Geles KG, Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin Cancer Res 1998;4:1533-42
   PubMed Web of Science ®Google Scholar
• Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003;10:43-73
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang W, Abruzzo LV, A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70
   PubMed Web of Science ®Google Scholar
• Ifergan I, Shafran A, Jansen G, Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 2004;279:25527-34
   PubMed Web of Science ®Google Scholar
• Imai Y, Asada S, Tsukahara S, Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 2003;64:610-18
   PubMed Web of Science ®Google Scholar
• Imai Y, Ishikawa E, Asada S, Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 2005;65:596-604
   PubMed Web of Science ®Google Scholar
• Wang Y, Cabral F. Paclitaxel resistance in cells with reduced beta-tubulin. Biochim Biophys Acta 2005;1744:245-55
   Google Scholar
• Giannakakou P, Sackett DL, Kang YK, Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25
   PubMed Web of Science ®Google Scholar
• Zhang CC, Yang JM, White E, The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 1998;16:1617-24
   PubMed Web of Science ®Google Scholar
• Shou J, Massarweh S, Osborne CK, Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35
   PubMed Web of Science ®Google Scholar
• Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25
   PubMed Web of Science ®Google Scholar
• Richardson ME, Siemann DW. Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance. Int J Radiat Oncol Biol Phys 1997;39:789-95
   PubMed Web of Science ®Google Scholar
• Dick JE. Stem cell concepts renew cancer research. Blood 2008;112:4793-807
   PubMed Web of Science ®Google Scholar
• Normanno N, Morabito A, De LA, Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer 2009;16:675-702
   PubMed Web of Science ®Google Scholar
• Li X, Lewis MT, Huang J, Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-9
   PubMed Web of Science ®Google Scholar
• Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009;138:822-9
   PubMed Web of Science ®Google Scholar
• Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010;220:263-80
   PubMed Web of Science ®Google Scholar
• Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008;26:2813-20
   PubMed Web of Science ®Google Scholar
• Charafe-Jauffret E, Monville F, Ginestier C, Cancer stem cells in breast: current opinion and future challenges. Pathobiology 2008;75:75-84
   PubMed Web of Science ®Google Scholar
• Shah SP, Morin RD, Khattra J, Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-13
   PubMed Web of Science ®Google Scholar
• Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007;117:3155-63
   PubMed Web of Science ®Google Scholar
• Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-71
   PubMed Web of Science ®Google Scholar
• Niemeyer CM. Semi-synthetic nucleic acid-protein conjugates: applications in life sciences and nanobiotechnology. J Biotechnol 2001;82:47-66
   PubMedGoogle Scholar
• Liu Z, Cai W, He L, In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2007;2:47-52
   PubMed Web of Science ®Google Scholar
• Weissleder R, Kelly K, Sun EY, Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 2005;23:1418-23
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86
   PubMed Web of Science ®Google Scholar
• Yuan F, Dellian M, Fukumura D, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6
   PubMed Web of Science ®Google Scholar
• Gaur U, Sahoo SK, De TK, Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 2000;202:1-10
   PubMed Web of Science ®Google Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63
   PubMed Web of Science ®Google Scholar
• Kannagi R, Izawa M, Koike T, Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004;95:377-84
   PubMed Web of Science ®Google Scholar
• Yamazaki N, Kojima S, Bovin NV, Endogenous lectins as targets for drug delivery. Adv Drug Deliv Rev 2000;43:225-44
   PubMed Web of Science ®Google Scholar
• Kornfeld S, Rogers J, Gregory W. The nature of the cell surface receptor site for Lens culinaris phytohemagglutinin. J Biol Chem 1971;246:6581-6
   PubMed Web of Science ®Google Scholar
• Seymour LW, Ferry DR, Anderson D, Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002;20:1668-76
   PubMed Web of Science ®Google Scholar
• Stewart FA, Dorr W. Milestones in normal tissue radiation biology over the past 50 years: from clonogenic cell survival to cytokine networks and back to stem cell recovery. Int J Radiat Biol 2009;85:574-86
   PubMed Web of Science ®Google Scholar
• McDonald SA, Graham TA, Schier S, Stem cells and solid cancers. Virchows Arch 2009;455:1-13
   PubMed Web of Science ®Google Scholar
• Fahmy TM, Fong PM, Park J, Nanosystems for simultaneous imaging and drug delivery to T cells. AAPS J 2007;9:E171-80
   PubMed Web of Science ®Google Scholar
• Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005;2:369-81
   PubMedGoogle Scholar
• Liu J, Li J, Rosol TJ, Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro. Phys Med Biol 2007;52:4739-47
   PubMed Web of Science ®Google Scholar
• Au L, Zheng D, Zhou F, A quantitative study on the photothermal effect of immuno gold nanocages targeted to breast cancer cells. ACS Nano 2008;2:1645-52
   PubMed Web of Science ®Google Scholar
• Noble CO, Guo Z, Hayes ME, Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol 2009;64:741-51
   PubMed Web of Science ®Google Scholar
• Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004;56:1127-41
   PubMed Web of Science ®Google Scholar
• Lu Y, Sega E, Leamon CP, Low PS. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev 2004;56:1161-76
   PubMed Web of Science ®Google Scholar
• Pattillo CB, Sari-Sarraf F, Nallamothu R, Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm Res 2005;22:1117-20
   PubMed Web of Science ®Google Scholar
• Khang D, Kim SY, Liu-Snyder P, Enhanced fibronectin adsorption on carbon nanotube/poly(carbonate) urethane: independent role of surface nano-roughness and associated surface energy. Biomaterials 2007;28:4756-68
   PubMed Web of Science ®Google Scholar
• Green LS, Jellinek D, Bell C, Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 1995;2:683-95
   PubMed Web of Science ®Google Scholar
• Harding JA, Engbers CM, Newman MS, Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta 1997;1327:181-92
   PubMed Web of Science ®Google Scholar
• Pattillo CB, Venegas B, Donelson FJ, Radiation-guided targeting of combretastatin encapsulated immunoliposomes to mammary tumors. Pharm Res 2009;26:1093-100
   PubMed Web of Science ®Google Scholar
• Scott RC, Wang B, Nallamothu R, Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction. Biotechnol Bioeng 2007;96(4):795-802
   PubMed Web of Science ®Google Scholar
• Scott R, Sun Y, Nallamothu R, Targeting model drug carriers and immunoliposomes to hypoxic areas in the infarcted heart. [abstract]. Proc. Fall BMES MTG 2004
   Google Scholar
• Scott RC, Crabbe D, Krynska B, Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue. Expert Opin Drug Deliv 2008;5:459-70
   PubMed Web of Science ®Google Scholar
• Kularatne SA, Low PS. Targeting of nanoparticles: folate receptor. Methods Mol Biol 2010;624:249-65
   PubMedGoogle Scholar
• Gradishar WJ, Tjulandin S, Davidson N, Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803
   PubMed Web of Science ®Google Scholar
• Wartlick H, Michaelis K, Balthasar S, Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 2004;12:461-71
   PubMed Web of Science ®Google Scholar
• Xu Y, Szoka FC Jr. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996;35:5616-23
   PubMed Web of Science ®Google Scholar
• Sakurai F, Inoue R, Nishino Y, Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression. J Control Release 2000;66:255-69
   PubMed Web of Science ®Google Scholar
• Sheff D. Endosomes as a route for drug delivery in the real world. Adv Drug Deliv Rev 2004;56:927-30
   PubMed Web of Science ®Google Scholar
• Chia S, Clemons M, Martin LA, Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006;24:2773-8
   PubMed Web of Science ®Google Scholar
• Jones RL, Berry GJ, Rubens RD, Miles DW. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol 2004;5:575-7
   PubMed Web of Science ®Google Scholar
• Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003;3:319-28
   PubMed Web of Science ®Google Scholar
• Lasic DD, Vallner JJ, Working PK. Sterically stabilized liposomes in cancer therapy and gene delivery. Curr Opin Mol Ther 1999;1:177-85
   PubMed Web of Science ®Google Scholar
• Nielsen UB, Kirpotin DB, Pickering EM, Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002;1591:109-18
   PubMed Web of Science ®Google Scholar
• Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer. Br J Cancer 2007;96:1315-19
   PubMed Web of Science ®Google Scholar
• Mamot C, Drummond DC, Noble CO, Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65:11631-8
   PubMed Web of Science ®Google Scholar
• Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res 2008;41:60-8
   PubMed Web of Science ®Google Scholar
• Kam NW, O'Connell M, Wisdom JA, Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci USA 2005;102:11600-5
   PubMed Web of Science ®Google Scholar
• Marx V. Poised to branch out. Nat Biotechnol 2008;26:729-32
   PubMed Web of Science ®Google Scholar
• Usui Y, Aoki K, Narita N, Carbon nanotubes with high bone-tissue compatibility and bone-formation acceleration effects. Small 2008;4:240-6
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007;24:1-16
   PubMed Web of Science ®Google Scholar
• Rhyner MN, Smith AM, Gao X, Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine (Lond) 2006;1:209-17
   PubMed Web of Science ®Google Scholar
• Xing Y, Chaudry Q, Shen C, Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc 2007;2:1152-65
   PubMed Web of Science ®Google Scholar
• Gao X, Cui Y, Levenson RM, In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22:969-76
   PubMed Web of Science ®Google Scholar
• Anas A, Okuda T, Kawashima N, Clathrin-mediated endocytosis of quantum dot-peptide conjugates in living cells. ACS Nano 2009;3:2419-29
   PubMed Web of Science ®Google Scholar
• Lidke DS, Nagy P, Heintzmann R, Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol 2004;22:198-203
   PubMed Web of Science ®Google Scholar
• Xiao Y, Gao X. Use of IgY antibodies and semiconductor nanocrystal detection in cancer biomarker quantitation. Biomark Med 2010;4:227-39
   PubMed Web of Science ®Google Scholar
• Weng KC, Noble CO, Papahadjopoulos-Sternberg B, Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett 2008;8:2851-7
   PubMed Web of Science ®Google Scholar
• Bailey RE, Nie S. Alloyed semiconductor quantum dots: tuning the optical properties without changing the particle size. J Am Chem Soc 2003;125:7100-6
   PubMed Web of Science ®Google Scholar
• Kim S, Fisher B, Eisler HJ, Bawendi M. Type-II quantum dots: CdTe/CdSe(core/shell) and CdSe/ZnTe(core/shell) heterostructures. J Am Chem Soc 2003;125:11466-7
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001;77:195-204
   PubMed Web of Science ®Google Scholar
• Liu HL, Hua MY, Chen PY, Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010;255:415-25
   PubMed Web of Science ®Google Scholar
• Pesic M, Podolski A, Rakic L, Ruzdijic S. Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil. Invest New Drugs 2010;28:482-92
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Vujaskovic Z, Kim DW, Jones E, A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia 2010;26:514-21
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius VR, Plummer CJ, Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Burzykowski T, Buyse M, Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008;26:1980-6
   PubMed Web of Science ®Google Scholar
• Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. J Support Oncol 2008;6:41-8
   PubMedGoogle Scholar
• Reichardt P, von MG, Thuss-Patience PC, Multicenter phase II study of oral capecitabine (Xeloda(″)) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-33
   PubMed Web of Science ®Google Scholar
• Jones S, Holmes FA, O'Shaughnessy J, Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 2009;27:1177-83
   PubMed Web of Science ®Google Scholar
• Fumoleau P, Cortes-Funes H, Taleb AB, Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. Am J Clin Oncol 2009;32(4):375-80
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL, Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41
   PubMed Web of Science ®Google Scholar
• Grady D, Cauley JA, Stock JL, Effect of Raloxifene on all-cause mortality. Am J Med 2010;123:469-7
   PubMed Web of Science ®Google Scholar
• Robertson JF, Llombart-Cussac A, Rolski J, Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-5
   PubMed Web of Science ®Google Scholar
• Neven P, Paridaens R, Pelgrims G, Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Res Treat 2008;109:59-65
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Jones SE, Vogel CL, A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997;79:730-9
   PubMed Web of Science ®Google Scholar
• Aihara T, Takatsuka Y, Ohsumi S, Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat 2010;121:379-87
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Langmuir VK, Sledge GW, A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-24
   PubMed Web of Science ®Google Scholar
• Seidman A, Hudis C, Pierri MK, Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21
   PubMed Web of Science ®Google Scholar
• Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am J Clin Oncol 2010;33:186-95
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00507429 [Last accessed 20 July 2010]
   Google Scholar
• Pili R, Rosenthal MA, Mainwaring PN, Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 2010;16:2906-14
   PubMed Web of Science ®Google Scholar
• Lin NU, Parker LM, Come SE, Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs 2007;25:369-75
   PubMed Web of Science ®Google Scholar
• Homsi J, Simon GR, Garrett CR, Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res 2007;13:5855-61
   PubMed Web of Science ®Google Scholar
• Seymour LW, Ferry DR, Kerr DJ, Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 2009;34:1629-36
   PubMed Web of Science ®Google Scholar
• Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev 2010; In press
   Google Scholar
• Lee KS, Chung HC, Im SA, Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008;108:241-50
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Wigler N, Inbar M, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9
   PubMed Web of Science ®Google Scholar
• Batist G, Harris L, Azarnia N, Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 2006;17:587-95
   PubMed Web of Science ®Google Scholar
• Lim WT, Tan EH, Toh CK, Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol 2010;21:382-8
   PubMed Web of Science ®Google Scholar
• Boulikas T. Clinical overview on lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 2009;18:1197-218
   PubMed Web of Science ®Google Scholar